share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股SEC公告 ·  08/21 04:28
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 08/20/2024, as per the latest filing. These shares, valued at approximately $81,532.92, were originally acquired as founder's shares on 09/01/2016 as compensation from the issuer. This planned sale follows a series of transactions over the past three months, where Borgeson sold a total of 68,682 Class A shares, generating gross proceeds of $569,369.77. The upcoming sale continues Borgeson's pattern of share disposals, which have been regularly occurring since May 2024.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 08/20/2024, as per the latest filing. These shares, valued at approximately $81,532.92, were originally acquired as founder's shares on 09/01/2016 as compensation from the issuer. This planned sale follows a series of transactions over the past three months, where Borgeson sold a total of 68,682 Class A shares, generating gross proceeds of $569,369.77. The upcoming sale continues Borgeson's pattern of share disposals, which have been regularly occurring since May 2024.
Recursion Pharmaceuticals, Inc.董事Blake Borgeson計劃於2024年08月20日出售11,447股A類公司股份,根據最新提交的申報文件。這些股份價值約爲$81,532.92,最初是在2016年09月01日作爲發行人的補償獲得的創始股份。這次計劃的出售是在過去三個月的一系列交易之後進行的,Borgeson出售了總共68,682股A類股份,獲得了569,369.77美元的總收益。即將到來的出售繼續了Borgeson的股份處置模式,這種模式自2024年5月以來一直定期發生。
Recursion Pharmaceuticals, Inc.董事Blake Borgeson計劃於2024年08月20日出售11,447股A類公司股份,根據最新提交的申報文件。這些股份價值約爲$81,532.92,最初是在2016年09月01日作爲發行人的補償獲得的創始股份。這次計劃的出售是在過去三個月的一系列交易之後進行的,Borgeson出售了總共68,682股A類股份,獲得了569,369.77美元的總收益。即將到來的出售繼續了Borgeson的股份處置模式,這種模式自2024年5月以來一直定期發生。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。